Clinical Trial Update: MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a CSF1R inhibitor for Alzheimer's disease and mild cognitive impairment was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• CSF1R inhibitor (colony-stimulating factor 1 receptor inhibitor)

Snippet

Sponsor: University of Oxford | Conditions: Alzheimer Disease, Mild Cognitive Impairment | Phase 1 | Status: TERMINATED